• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Differences in predictors of 5‐year survival over a 10‐year period in two cohorts of elderly nursing home residents in Sweden
ConclusionsThe present results indicate a trend that individuals are older and frailer when admitted to NH and that survival time after admission has been shortened. Hence, the need of daily support and care has increased, irrespective of housing. Also, predictors of survival, possible to influence, have changed.
Source: Scandinavian Journal of Caring Sciences - February 4, 2016 Category: Nursing Authors: Märta Sund Levander, Anna Milberg, Nils Rodhe, Pia Tingström, Ewa Grodzinsky Tags: Empirical Studies Source Type: research

Differences in predictors of 5 ‐year survival over a 10‐year period in two cohorts of elderly nursing home residents in Sweden
ConclusionsThe present results indicate a trend that individuals are older and frailer when admitted to NH and that survival time after admission has been shortened. Hence, the need of daily support and care has increased, irrespective of housing. Also, predictors of survival, possible to influence, have changed.
Source: Scandinavian Journal of Caring Sciences - February 3, 2016 Category: Nursing Authors: M ärta Sund Levander, Anna Milberg, Nils Rodhe, Pia Tingström, Ewa Grodzinsky Tags: Empirical Studies Source Type: research

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news